Emerald Health Pharmaceuticals

5 articles about Emerald Health Pharmaceuticals

• Emerald Health Pharmaceuticals Expands Scientific Advisory Board with the Appointment of Neuroscience Expert Dr. Eduardo Candelario-Jalil

  5/24/2021

  Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet medical needs, has expanded its Scientific Advisory Board with the appointment of neuroscience expert and innovator, Eduardo Candelario-Jalil, PhD.

• Emerald Health Pharmaceuticals Announces Final Closing Date For its Regulation A+ Offering

  3/9/2021

  Emerald Health Pharmaceuticals Inc. (EHP, or, the Company), a clinical-stage biotechnology company developing a new class of medicines to treat diseases with unmet medical needs, has announced a final closing date for its Regulation A (“Reg A”) offering due to expiration of the Company’s Offering Statement.

• Emerald Health Pharmaceuticals Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis

  3/8/2021

  Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases with unmet medical needs, has initiated activities for a Phase 2 international clinical study for the treatment of patients with multiple sclerosis (MS).

• Emerald Health Pharmaceuticals' Scientific Team Leads Cannabinoid Research Showing Potential To Impact Neurodegenerative Diseases

  9/20/2017

  These results were published in the British Journal of Pharmacology in a paper entitled, “Tetrahydrocannabinolic acid is a potent PPAR? agonist with neuroprotective activity.”

• Emerald Health Pharmaceuticals To Treat Life-Threatening Diseases With Novel Synthetic Cannabinoid-Derived Molecules

  9/15/2017

  Emerald Health Pharmaceuticals Inc. (EHP) today announced its mission to discover, develop and commercialize novel synthetic cannabinoid-derivative drug candidates to treat life-threatening diseases.